Welcome to our dedicated page for Whitehawk Therapeutics SEC filings (Ticker: WHWK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Whitehawk Therapeutics, Inc. (Nasdaq: WHWK) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Whitehawk is a clinical-stage oncology therapeutics company focused on antibody-drug conjugate (ADC) cancer treatments, and its filings offer insight into financial results, development plans and corporate activities related to this strategy.
Among the key documents available are current reports on Form 8-K, which Whitehawk has used to furnish press releases announcing quarterly financial results and recent highlights. These filings reference information such as research and development spending, progress toward Investigational New Drug (IND) submissions for ADC programs like HWK-007 and HWK-016, and updates on the company’s three-asset ADC portfolio targeting PTK7, MUC16 and SEZ6.
On this page, users can also locate Whitehawk’s annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically contain more detailed discussions of the company’s oncology pipeline, risk factors, and financial condition. For investors interested in governance and compensation matters, proxy materials and related filings can provide additional context on board and executive oversight of the ADC development strategy.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly understand major updates without having to parse every page. Real-time updates from the SEC’s EDGAR system ensure that new WHWK filings, including future 10-Ks, 10-Qs and 8-Ks, appear promptly. Users can also review insider transaction reports on Form 4, when available, to see reported trades by directors and officers.
Together, these resources give a structured view of how Whitehawk reports its financial performance, clinical progress and corporate decisions to regulators and the market.
Whitehawk Therapeutics insider Bryan Ball reported dispositions of company common stock that were executed solely to cover taxes on equity compensation. On April 9 and 10, he completed broker-assisted sales totaling 56,596 shares at prices between $3.43 and $3.57 per share.
The footnote explains these trades were conducted to satisfy tax withholding obligations arising from the vesting of restricted stock units, rather than discretionary open-market sales. After these transactions, Ball still directly holds 515,955 shares of Whitehawk Therapeutics common stock.
Whitehawk Therapeutics, Inc. director and chief executive officer David James Lennon reported selling 14,500 shares of common stock on April 9, 2026 at $3.38 per share. According to the filing, this broker-assisted sale was made solely to satisfy tax withholding obligations tied to vesting restricted stock units. After the transaction, he directly holds 518,622 shares of Whitehawk common stock.
Whitehawk Therapeutics (WHWK) filed a Form 144 reporting an intended sale of 366,532 Restricted Stock Units with an applicable date of 04/01/2026. The filing shows 1,834 shares of Common Stock were sold on 03/02/2026 for $6,069.80.
David James Lennon reported multiple Rule 144 sales of Common Stock of WhiteHawk Therapeutics. The filing lists specific dispositions on 03/02/2026 and 04/02/2026–04/08/2026, including sales of 5,100 shares and 102,395 shares on those dates respectively.
The notice also lists 775,828 Restricted Stock Units dated 04/01/2026.
Whitehawk Therapeutics director and CEO David James Lennon sold shares to cover taxes tied to equity vesting. Over April 6–8, 2026, he executed broker-assisted sales totaling 260,427 shares of Common Stock at prices around $3.40–$3.51 per share.
According to a footnote, these transactions were made solely to satisfy his tax withholding obligations in connection with the vesting of restricted stock units, rather than discretionary open-market sales. After these dispositions, he directly holds 533,122 Common Stock shares.
Whitehawk Therapeutics, Inc. granted Chief Scientific Officer David Dornan a stock option to acquire 282,340 shares of common stock at an exercise price of $3.54 per share, expiring on April 1, 2036.
According to the vesting terms, if he continues as a service provider, 25% of the option will vest on the one-year anniversary of the Vesting Commencement Date of April 1, 2026, with the remaining shares vesting in equal monthly installments over the following three years.
Whitehawk Therapeutics, Inc. reported that its Chief Medical Officer, Margaret Dugan, received a grant of stock options covering 283,157 shares of common stock. The options have an exercise price of $3.54 per share and expire on April 1, 2036.
These options were granted as compensation and will vest over four years. Twenty five percent of the shares will vest on the one-year anniversary of the April 1, 2026 vesting commencement date, with the remaining shares vesting in equal monthly installments until fully vested.
Whitehawk Therapeutics, Inc. executive Bryan Ball reported compensation-related equity activity. He exercised 366,532 restricted stock units, receiving the same number of common shares at a price of $0.00 per share. Following this RSU conversion, he directly held 572,551 shares of common stock.
Ball was also granted a new stock option for 250,058 shares of common stock with an exercise price of $3.54 per share, expiring on April 1, 2036. According to the footnotes, RSUs vest 100% one year after the April 1, 2025 vesting commencement date, and the option vests over four years starting April 1, 2026, assuming continued service.
Whitehawk Therapeutics, Inc. reported that Chief Financial Officer Scott M. Giacobello exercised restricted stock units and received a new stock option grant. He exercised 473,902 restricted stock units, receiving the same number of common shares, and now directly holds 502,002 common shares. He was also granted a stock option for 300,677 shares of common stock at an exercise price of $3.54 per share, expiring on April 1, 2036. According to the footnotes, the RSU award vests 100% on the one-year anniversary of the April 1, 2025 vesting commencement date, while the option vests over four years starting from an April 1, 2026 vesting commencement date.
Whitehawk Therapeutics, Inc. director and CEO David James Lennon exercised restricted stock units and received a new stock option award, while selling a small block of shares to cover taxes. He exercised 775,828 restricted stock units, receiving the same number of Common Stock shares. He also received a stock option for 831,148 shares of Common Stock at an exercise price of $3.54 per share, expiring on April 1, 2036, subject to multi‑year vesting. To satisfy tax withholding obligations related to RSU vesting, a broker-assisted sale of 26,858 shares of Common Stock was executed at $3.48 per share. After these transactions, Lennon directly holds 793,549 Common Stock shares.